Healthcare and Medical
Healthcare and Medical
home | healthcare and medical | market report
Forecast Insight - Multiple Sclerosis (Datamonitor)
- Market: Healthcare and Medical
- Published Date: 20/08/2008
- Report Title: Forecast Insight - Multiple Sclerosis
- Table of Contents: View Table of Contents
- Report Type: Market Report
- Country: Global
- Number of Pages: 127
Overview
Introduction
Spurred by uptake of Biogen Idec and Elan's Tysabri (natalizumab) and continued revenue growth for the three beta-interferon brands and Teva's Copaxone (glatiramer acetate), the seven major multiple sclerosis market value increased 15.1% from 2006 to $5.3 billion in 2007.
Scope
This report gives a strategic analysis of the likely impact that recent events will have on the future multiple sclerosis market
Includes multiple sclerosis-specific sales forecasts for the key brands and pipeline agents in the seven major markets to 2017
Provides a global market snapshot by including multiple sclerosis-specific sales analysis for leading brands outside the seven major markets
Key conclusions are supported by key opinion leader comment
Report Highlights
Despite the recent confirmation of two new cases of progressive multifocal leukoencephalopathy (PML), with a much stronger 2007-08 enrollment rate than previously anticipated and a greater level of confidence among opinion leaders, Datamonitor has upgraded its Tysabri's forecast.
Datamonitor remains highly positive on Novartis's FTY720 (fingolimod). FTY720 is expected to achieve the greatest sales of all current late-stage pipeline products. However, sales growth will be restricted from 2012 by the later launch of additional oral pipeline disease-modifiers, which will represent tough direct competition.
Genzyme and Bayer Schering's alemtuzumab (Campath) has been added to this latest multiple sclerosis forecast. Potentially positioned in both the earliest stages of the disease and for rapidly progressing patients refractory on other therapies, a poor perceived safety profile and an assumed low price-point, will limit returns from this market.
Reasons to Purchase
Understand when late-stage pipeline products will launch and what impact these will have on the market during the forecast period 2008 to 2017
Quantify the current size of the seven major markets and the trends in the rest of the world
Assess the impact of events, such as patent expiries and new product launches, on the multiple sclerosis-specific sales of key brand name products
Introduction
Spurred by uptake of Biogen Idec and Elan's Tysabri (natalizumab) and continued revenue growth for the three beta-interferon brands and Teva's Copaxone (glatiramer acetate), the seven major multiple sclerosis market value increased 15.1% from 2006 to $5.3 billion in 2007.
Scope
This report gives a strategic analysis of the likely impact that recent events will have on the future multiple sclerosis market
Includes multiple sclerosis-specific sales forecasts for the key brands and pipeline agents in the seven major markets to 2017
Provides a global market snapshot by including multiple sclerosis-specific sales analysis for leading brands outside the seven major markets
Key conclusions are supported by key opinion leader comment
Report Highlights
Despite the recent confirmation of two new cases of progressive multifocal leukoencephalopathy (PML), with a much stronger 2007-08 enrollment rate than previously anticipated and a greater level of confidence among opinion leaders, Datamonitor has upgraded its Tysabri's forecast.
Datamonitor remains highly positive on Novartis's FTY720 (fingolimod). FTY720 is expected to achieve the greatest sales of all current late-stage pipeline products. However, sales growth will be restricted from 2012 by the later launch of additional oral pipeline disease-modifiers, which will represent tough direct competition.
Genzyme and Bayer Schering's alemtuzumab (Campath) has been added to this latest multiple sclerosis forecast. Potentially positioned in both the earliest stages of the disease and for rapidly progressing patients refractory on other therapies, a poor perceived safety profile and an assumed low price-point, will limit returns from this market.
Reasons to Purchase
Understand when late-stage pipeline products will launch and what impact these will have on the market during the forecast period 2008 to 2017
Quantify the current size of the seven major markets and the trends in the rest of the world
Assess the impact of events, such as patent expiries and new product launches, on the multiple sclerosis-specific sales of key brand name products
Purchase Information
There are various ways to purchase products from our site. Select the report title(s) you are interested in, and add it to your basket. At the Checkout page, you will be requested to submit your details. You will then have the option to pay via various methods: Debit Card ; Credit Card ; Purchase via Invoice (inc. Purchase Order no. if required) and Paypal. Companiesandmarkets.com accepts Visa, MasterCard, Diners, American Express, JCB and all the major credit cards. Companiesandmarkets.com uses RBSWorldpay.
Once you have purchased your report(s), you will receive a confirmation email. You will then either be able to download your report(s) immediately from your Customer Area in PDF format, or the report(s) will be emailed to you directly, depending on the agreement we have with the publisher. Orders that are deliverable via email which are taken outside of working hours will be delivered next business day.
Please note, if you purchase by invoice, you will receive your report(s) once payment has been received. If you have any questions about how to order, please Contact Us.
